One of the largest and longest follow-ups of patients implanted with the subcutaneous-lead implantable cardioverter defibrillator (S-ICD), now marketed as the EMBLEM S-ICD (Boston Scientific), paints ...

Patients who require a new permanent pacemaker after TAVI do just as well with leadless devices out to 2 years as they do with transvenous pacemakers, according to an analysis of real-world data from ...

A 67-year-old man with acute anterolateral myocardial infarction had recurrent ventricular fibrillation that required insertion of temporary pacemaker. When a permanent pacemaker was inserted stable ...

Please provide your email address to receive an email when new articles are posted on . “Prior research has established the subcutaneous ICD as a reasonable alternative to the transvenous ICD in ...

There are unique technical issues that must be considered with the implantation of devices in small patients and those with CHD. Although most centers report low complication rates of complications in ...

BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study ...

MENLO PARK, Calif.--(BUSINESS WIRE)--BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo ® Temporary Pacing Lead was featured in a ...

NEW ORLEANS -- A leadless dual-chamber pacemaker with bidirectional wireless communication turned in very promising short-term results in patients with standard indications for dual-chamber pacing, ...

Please provide your email address to receive an email when new articles are posted on . The first pacemaker implantation was performed in 1958, and the technology has undergone many advances since ...